摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate | 222554-31-6

中文名称
——
中文别名
——
英文名称
(+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate
英文别名
(+)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate;ethyl 2-ethoxy-3-[4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl]propanoate
(+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate化学式
CAS
222554-31-6
化学式
C23H27NO6
mdl
——
分子量
413.47
InChiKey
HDNXFFDAIVBYBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    30
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    74.3
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate 在 sodium carbonate 作用下, 以 甲醇 为溶剂, 以93%的产率得到(+/-)-2-Ethoxy-3-[4-[2-[4-oxo-3,4-dihydro 1,3 benzoxazin-3-yl]ethoxy]phenyl]propanoic acid
    参考文献:
    名称:
    Benzothiazin and benzoxazin derivatives; their preparation and uses
    摘要:
    本发明涉及新型抗肥胖和降胆固醇化合物,它们的衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说,本发明涉及一般式(I)的新型β-芳基-α-氧基取代烷基羧酸,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。
    公开号:
    US06130214A1
  • 作为产物:
    描述:
    ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]-2-propenoate 在 氢气 作用下, 以 1,4-二氧六环 、 palladium charcoal 为溶剂, 以78%的产率得到(+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate
    参考文献:
    名称:
    Benzothiazin and benzoxazin derivatives; their preparation and uses
    摘要:
    本发明涉及新型抗肥胖和降胆固醇化合物,它们的衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说,本发明涉及一般式(I)的新型β-芳基-α-氧基取代烷基羧酸,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。
    公开号:
    US06130214A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVELLES COMPOSITIONS HETEROCYCLIQUES ET LEUR UTILISATION EN MEDECINE; PROCEDES DE LEUR FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:DR. REDDY'S RESEARCH FOUNDATION
    公开号:WO1999016758A1
    公开(公告)日:1999-04-08
    (EN) The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.(FR) La présente invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant. Plus particulièrement, cette invention se rapporte à de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués qui correspondent à la formule générale (I), ainsi qu'à leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et à des compositions pharmaceutiquement acceptables les contenant.
    本发明涉及新型抗肥胖和降低胆固醇化合物,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。更具体地说,本发明涉及一般式(I)的新型$g(b)-芳基-$g(a)-氧基取代的烷基羧酸,其衍生物,类似物,互变异构体,立体异构体,多晶形态,药学上可接受的盐,药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。
  • Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
    申请人:DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC.
    公开号:US20010027198A1
    公开(公告)日:2001-10-04
    The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (1), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1 The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.
    本发明涉及新型抗肥胖和降胆固醇化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。更具体地,本发明涉及一般式(1)的新型β-芳基-α-氧基取代烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。本发明还涉及制备上述新型化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和含有它们的制药组合物的方法。
  • NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE
    申请人:LOHRAY Braj Bhushan
    公开号:US20080188402A1
    公开(公告)日:2008-08-07
    The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.
    本发明涉及新的取代吡咯化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组成物。本发明特别涉及一般式(I)的新的取代吡咯化合物、它们的类似物、衍生物、多晶形态、互变异构体、药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组成物。本发明还涉及制备这种化合物的过程、含有这种化合物的组成物以及这种化合物和组成物在医学上的使用。
  • Heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
    申请人:Dr. Reddy's Laboratories Limited
    公开号:US06664411B2
    公开(公告)日:2003-12-16
    The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.
    本发明涉及一种新型的抗肥胖和降胆固醇的化合物,它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。更具体地,本发明涉及一种新型的β-芳基-α-氧基取代烷基羧酸的一般式(I),它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明还涉及一种制备上述新化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和含有它们的制药组合物的方法。
  • Intermediates of benzoxazinone derivatives and preparation thereof
    申请人:Reddy's Laboratories Ltd.
    公开号:US06331627B1
    公开(公告)日:2001-12-18
    The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereo-somers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.
    本发明涉及一种新型的抗肥胖和降低胆固醇的化合物,它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。更具体地说,本发明涉及一种新型的β-芳基-α-氧基取代的烷基羧酸,其一般式为(I),其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。本发明还涉及一种制备上述新型化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和包含它们的药物组合物的方法。
查看更多